Clinical Trial Update: 68Ga-THP-PSMA PET/CT Imaging in High Risk Primary Prostate Cancer or Biochemical Recurrence of Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on 68Ga-THP-PSMA PET/CT imaging for high-risk primary or recurrent prostate cancer; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 68Ga-THP-PSMA PET/CT imaging (68Ga-THP-PSMA)

Snippet

Sponsor: Theragnostics Ltd | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-06-24